{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:37:10Z","timestamp":1774489030729,"version":"3.50.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1093\/jjco\/hyw194","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T23:14:17Z","timestamp":1487891657000},"page":"551-559","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial"],"prefix":"10.1093","volume":"47","author":[{"given":"Masafumi","family":"Oyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Hinotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"key\n\t\t\t\t20170530062442_hyw194C1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","year":"2005","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20170530062442_hyw194C2","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170530062442_hyw194C3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170530062442_hyw194C4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000209961","article-title":"Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib","volume":"76","year":"2009","journal-title":"Oncology"},{"key":"key\n\t\t\t\t20170530062442_hyw194C5","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","article-title":"Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170530062442_hyw194C6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdv612","article-title":"Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)","volume":"27","year":"2016","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20170530062442_hyw194C7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyq166","article-title":"Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1","volume":"41","year":"2011","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/47\/6\/551\/17634501\/hyw194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T18:43:57Z","timestamp":1503600237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyw194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,3,1]]},"published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw194","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}